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Abstract
Background: Mutations activating the α subunit of heterotrimeric Gs protein are associated with a number of
highly specific pathological molecular phenotypes. One of the best characterized is the McCune Albright syndrome.
The disease presents with an increased incidence of neoplasias in specific tissues.
Main body: A similar repertoire of neoplasms can develop whether mutations occur spontaneously in somatic
tissues during fetal development or after birth.
Glands are the most “permissive” tissues, recently found to include the entire gastrointestinal tract. High frequency
of activating Gαs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic
adenoma). Typically, most neoplastic lesions, from thyroid to pancreas, remain well differentiated but may be a
precursor to aggressive cancer.
Conclusions: Here we propose the possibility that gain-of-function mutations of Gαs interfere with signals in the
microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
Keywords: GNAS, Heterotrimeric Gs protein, Activating mutation, Neoplasm, McCune Albright Syndrome,
Intraductal papillary mucinous neoplasm, Fibrous dysplasia
Background
Heterotrimeric Gαβγ proteins are central to sensing a
great number of extracellular stimuli. Each of the sub-
units is encoded by a multigene family that accommo-
dates coupling to a huge diversity of seven
transmembrane receptors. In metazoan organisms, four
classes of Gα subunits, Gs, Gi, Gq and G12, couple sev-
eral hundreds receptors to distinct sets of effector pro-
teins. The Gs class of alpha subunits includes two genes
GNAS and GNAL encoding Gαs and Gαolf proteins re-
spectively that stimulate the effector protein adenylyl cy-
clase and regulate certain ion channels.
Whole genome analysis revealed that mutations affect-
ing G proteins and GPCRs are more frequent than pre-
viously thought in transformed cells [1]. In a growing
number of neoplasias, two hotspots on Gαs, Arg (R)201
and Gln (Q)227, are found mutated to three (Cys/His/
Ser) or two (Arg/Leu) amino acids, respectively (Fig. 1a).
By contrast, activating mutations in Gαolf have not been
found. In Gαs, R201 mutations are more common than
Q227 but substitutions at either residue inhibit intrinsic
GTPase catalytic activity. The crystal structure shows
these residues contribute to transition state interactions
during GTP hydrolysis [2] (Fig. 2). As a consequence,
mutant Gαs with substitutions at either residue remains
GTP-bound, persisting in an active state that prolongs
the effector protein interaction with dissociated Gαs or
βγ. Cholera toxin achieves an equivalent result by ADP
ribosylating R201 [3].
The TCGA database shows tissue distribution of Gαs
activating mutations among 29 cancers (Table 1, Fig. 1b).
An obvious indication for a cancer subtype is not evident.
However, recent data point to certain highly prevalent
neoplasms not included in the TCGA database (Table 2
and reference therein). The frequency of Gαs activating
mutations in adenocarcinoma is comparable between the
two data sets. The striking difference is the common
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occurrence of Gαs activating mutations in adenoma and
other early neoplasia in neuroendocrine tumors. (Table 2).
Gαs is associated with neoplasia and cancer but not Gαolf,
probably because Gαs is ubiquitously expressed at high
levels whereas Gαolf is highly expressed only in olfactory
epithelium and other specialized cells (Fig. 1), and tumors
from those tissues have not been well characterized. These
features of effector protein regulation and expression pat-
tern influence the oncogenic potential of Gs class genes.
Equivalent activating mutations of the Gq class pro-
teins Gαq and Gα11 occur in virtually all blue naevi [4],
and for Gαi2, in ovary and adrenal gland [5]. These acti-
vating mutations in Gα genes are analogous to onco-
genic mutations in the small G protein Ras which inhibit
GTP hydrolysis [6], present in about 30% of all tumors,
reaching nearly 100% in specific types [7]. Such specific
mutation profiles in G alpha genes, tightly linked to
gain-of-function in benign neoplasia and some aggres-
sive cancers, leaves little doubt about the selective ad-
vantage provided by the mutation to transforming cells.
Yet, how this molecular mechanism contributes to the
pathogenesis remains obscure.
Main body
GNAS and the activating mutation
Gαs is encoded by the GNAS locus. This is a highly
complex gene with alternative promoters controlling the
Fig. 1 GNAS/GNAL Cross Cancer Comparison in Human Tumor Samples based on TCGA provisional data. Cbioportal was used to generate figures. a
Mutational Diagrams. No activating alleles were found in GNAL. Two activating alleles were found in GNAS producing residues substitutions at R201
and Q227 (see in the text). b Expression Level Diagrams. GNAS shows higher expression level compared to GNAL in a cross cancer comparison
Fig. 2 3-D model of GαS. Residues 40 to 394 of Gαs are represented
based on protein model portal, template 3sn6A. The GTP binding
domains are indicated in yellow, the most common gsp mutations,
at R201 (the target of Cholera toxin) and Q227, are indicated in red
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expression of multiple transcripts. Gαs is also regu-
lated by genomic imprinting. In a few specific tissues,
including the renal proximal tubule, the thyroid, the
pituitary, and the gonads, one of the two alleles,
usually the father’s, is silenced by methylation during
development [8, 9].
In humans, germline transmission of Gαs activating
mutations is not observed, suggesting they are embry-
onic lethal. However, postzygotic activating mutations
are maintained through somatic mosaicism, causing
McCune Albright Syndrome (MAS, MIM#174800).
Predominant MAS symptoms are related to endocrine
tumors (principally in pituitary, ovarian, adrenal and
thyroid glands), skin pigmentation (cafè au lait) and
polyostotic fibrous dysplasia.
When somatic mutations occur during adult life,
the phenotype emerges independently in the same
“permissive” tissues affected in MAS and displays
analogous symptoms to postzygotic mosaicism. Over
a quarter century ago, a direct link between GNAS
gain-of-function mutations and cell transformation
was established in growth hormone (GH)-secreting
pituitary adenoma of acromegalic patients and in
small subsets of other endocrine tumors [6, 10]. The
constitutively active forms of GNAS (Fig. 2), gene-
rated by the hotspot mutations described in the pre-
vious paragraph, were collectively named gsp in
recognition of their oncogenic potential.
Gsp, the microenvironment and precursor cell maturation
The hypothalamic hypophysiotropic hormone (GHRH)
is the principal regulator of secretory and proliferative
functions of somatotrophs [11]. Gαs directly couples the
GHRH receptor to its downstream effector proteins.
This fully explains the secretory properties of pituitary
adenoma that are common to most gsp+ tumors discov-
ered, including exocrine (mostly mucous) and endocrine
subtypes. The last category could be extended to dyspla-
sia involving the bone marrow, as it produces signals
that regulate other organs in the body (i.e. osteocalcin
targeting pancreas and testis or fibroblast growth factor-
23 (FGF-23) targeting kidney [12]).
In fibrous dysplasia (FD) gsp prevalence is over 80%
(Table 2 at the bottom). Patients affected by this uncom-
mon bone disorder present fibrous tissue in place of
normal bone with lesions reflecting the dysfunction of
osteogenic progenitors. The protein product of gsp indir-
ectly promotes transcription of the proto-oncogene c-fos
specifically in the marrow of affected bones [13]. In
addition, the expression of osteoblast-specific genes is
inhibited while IL-6 expression is increased, thus pro-
moting the action of osteoclasts [14]. As a result,
unorganized and poorly mineralized woven bone is ob-
served with the retraction of osteogenic cells from the
bone surface and the formation of Sharpey’s fibers.
Hematopoietic marrow is replaced by fibrotic marrow
with characteristics of osteogenic progenitors that
Table 1 Activating alleles of Gαs and/or Rαs in cBioPortal cancer cohorts
Cancer Study Type GNASb (%c) GNASa,b RASb RASb Percent Total Samples
AML 0 0 21 (11%) 191
Bladder 0 0 0 (0%) 131
Breast Cohort 1 1 0 6 (1%) 816
Breast Cohort 2 1 0 3 (1%) 482
Renal Clear Cell Carcinoma 0 0 0 (0%) 499
Colorectal Adenocarcinoma 1 0 91 (43%) 212
Head and Neck Squamous Cell 0 0 0 (0%) 279
Diffuse Glioma 0 0 8 (1%) 794
Lung Adenocarcinoma 2 (2%) 2 76 (33%) 230
Lung Squamous Cell Carcinoma 0 0 0 (0%) 178
Pan-Lung Cancer 5 (<1%) 3 232 (20%) 1144
High Grade Serous Ovarian Cancer 0 0 4 (1%) 316
Pancreatic Adenocarcinoma 7 (5%) 3 138 (93%) 149
Prostate Adenocarcinoma 0 0 0 (0%) 333
Stomach Adenocarcinoma 3 (1%) 1 28 (10%) 287
Papillary Thyroid Cancer 0 0 0 (0%) 507
Uterine Endometrial Carcinoma 0 0 51 (21%) 240
aCoincidence of GNAS and KRAS activating mutations. Among the cancer cohorts from TCGA in cBioPortal [100, 101], pancreatic adenocarcinoma, pan-lung, and
stomach cancers had the highest frequencies of activating alleles of Gαs in the absence of KRAS mutations
bActivating alleles of GNAS and/or KRAS
c% GNAS activating alleles with two or more occurrences in the cancer cohort
Innamorati et al. BMC Cancer  (2018) 18:293 Page 3 of 15
Table 2 Incidence of “gsp” in “receptive organs”
Site Histology (Dysplasia/Neoplasia) Incidence % (n) Refs
Thyroid Toxic thyroid adenoma 23% (65) [102–104]
Non functional adenoma 0% (31) [102, 104]
Carcinoma 0% (18) [104, 105]
Pituitary GH-secreting adenoma 41% (504) [106–126]
Prolactin-secreting adenoma 0% (7) [107]
Non functioning 3% (32) [107]
Muscle Intramuscolar myxoma 45% (101) [39, 127, 128]
Various myxoid lesions 0% (105) [39, 127–130]
Bone Fibrous dysplasia (FD) 81% (414) [127, 131–134]
Low grade periosteal osteosarcoma 0% (11) [135]
Low grade central osteosarcoma 3% (35) [135–137]
Low grade parosteal osteosarcoma 0% (80) [135, 137]
Osteofibrous dysplasia 0% (13) [132, 134, 138]
Ossifying fibroma 0% (66) [131, 132]
Blood Hematological conditions 0.6% (512) [139–141]
Kidney Renal cell carcinoma 17% (30) [142]
Lung Mucinous cystoadenoma 0.5% (208) [24, 68, 143]
Pancreas Intraduct. Papill. Mucin. Neop.(IPMN) 58% (809) [17, 19–21, 30, 68, 144–148]
Incipient IPMN 33% (21) [149]
Intraduct. Tubulopapill. Neop. (ITPN) 60% (15) [146]
Intraepithelial neoplasia (PanIN) 2% (246) [20, 150]
Serous cystoadenoma (SCN) 0% (54) [20, 144]
Mucin. Cyst.Neop. (MCN) 0% (31) [20, 144]
Neuroendocrine tumor 0% (52) [20]
Ductal adenocarcinoma (PDAC) 0.4% (253) [20, 30, 144, 145, 150]
Biliary tract IPMN of the bile duct 23% (120) [42, 151–153]
Biliary intraepithelial neoplasia 1% (82) [153, 154]
Stomach Pyloric gland adenoma 48% (23) [41]
Gastric adenocarc. of the fundic gland 24% (29) [64, 74]
Hyperplastic gastric polyps 0% (10) [127]
Foveolar type adenoma 0% (23) [41]
Intestinal type adenoma 0% (34) [41]
Gastric adenocarcinoma 0% (71) [41]
Duodenum Pyloric gland adenoma 92% (35) [41]
Gastric foveolar metaplasia 41% (66) [66]
Gastric heterotopia 28% (81) [66]
Adenocarcinoma 17% (30) [66]
Gastroent. neuroen. tum. (GEP-NET) 0% (31) [155]
Colon-rectum Villous adenoma 67% (55) [155–158]
Tubular villous adenoma 4% (154) [155–157]
Tubular adenoma 0% (28) [155, 157]
Polyps 0% (45) [156]
Adenocarcinoma 3% (820) [68, 155–159]
Liver Normal liver Intrahepat.cholangioc 12%(43) [160]
Innamorati et al. BMC Cancer  (2018) 18:293 Page 4 of 15
hyperproliferate but cannot completely differentiate into
osteoblasts. Surprisingly, the mutation introduced in a
murine zygote was transmissible. It did not produce
endocrine neoplasm but did replicate human fibrous
dysplasia [15]. In this animal model, the expression of
mutant Gαs was achieved by viral transduction thus
leaving the natural GNAS locus unaffected. Despite this
bias, the experiment proved that functional up-
regulation of Gαs, per se, preserves most functional as-
pects specific of stem cells or of osteoblastic progenitors
but it compromises cell organization in the tissue.
In summary, by conditioning stem cell maturation, gsp
dramatically compromises the hematopoietic micro-
environment leading to abnormal histology [16].
An analogous picture is emerging in a number of rare
and well-differentiated neoplastic forms, with gsp affect-
ing cellular organization of permissive mature tissues.
Acting early during tumor progression, gsp prevents the
correct maturation of cell precursors possibly unbalan-
cing intracellular signaling relevant to cell maturation.
The list of gsp tumors dramatically extended in the last
few years (Table 2) covering virtually all regions of the
gastroenteric tract, from gastric to colorectal mucosa in-
cluding accessory organs such as pancreas and liver.
As for bone and pituitary, the mutation is likely under-
lining a signaling pathway pivoting around cAMP (see
below) that is sufficient to distort tissue differentiation
or maintenance but only exceptionally to guide full
malignant transformation.
The first report to identify gsp in the digestive tract de-
scribes a screen for biomarkers discriminating among
pancreatic cysts [17]. These lesions are pockets filled with
fluids. Quite common with aging, cysts are usually re-
vealed by radiology exams. Cysts pose a serious clinical
challenge, as occasionally they may be cancerous and
justify surgical intervention. Yet, the final diagnosis can
only be made by histological exam of the resected organ.
Gsp was identified as a sensitive and specific marker of
intraductal papillary mucinous neoplasm (IPMN). Al-
though it remains debated if IPMN should be considered
a direct precursor of pancreatic ductal adenocarcinoma
(PDA), the treatment of choice is resection since patients
with IPMN are at high risk to develop PDA [18].
Gsp is present in low grade IPMN and does not
increase with the level of the dysplasia [19]. Discrimi-
nating IPMN in two subgroups, namely mucinous/in-
testinal and tubular subtypes, Hosoda et al. frequently
found gsp in the first group, considered more indolent
[20]. Tamura et al. reported analogous findings
although no correlation was found between GNAS
status and IPMN histologic grade or clinical characte-
ristics, including patient postoperative outcomes [21].
IPMN substantially lacks significant symptoms. None-
theless, there is a latent but significant impact of gsp and
Table 2 Incidence of “gsp” in “receptive organs” (Continued)
Site Histology (Dysplasia/Neoplasia) Incidence % (n) Refs
Advanc. Intrahepatic cholangiocarc 3% (38) [160]
Hepatocell. Adenoma 4% (179) [22, 161]
Hepatocell. Carcinoma 0.8% (245) [22]
Fluke-ass. cholangiocarcinoma 9.3% (53) [23]
Appendix Low grade app. muc. neop. (LAMN) 43% (84) [31, 40, 68, 162, 163]
Adenocarcinoma 46% (106) [31, 40, 68, 69, 162–164]
Gonads Leydig cell stromal tumor 67% (6) [165]
Lobular Endocer. Glandular Hyperpl. 28% (32) [166]
Juvenile Ovarian granul. cell tumor 30% (30) [167]
Mucinous cystoadenoma 9% (45) [68, 168]
Mucinous border line tumor 4% (53) [68, 168]
Mucinous cystadenocarcinoma 2% (45) [68, 168]
Ovarian granulosa cell tumor 0% (25) [169, 170]
Other sex cord stromal tumors 0% (6) [170]
Adenocarcinoma 4% (92) [166]
Squamous cell carcinoma 0% (43) [166]
Adrenocortical Cortisol producing adenoma 20% (25) [28, 90, 171]
Adrenocrotical Carcinoma 3% (40) [80]
An extensive list of neoplasias, flanked by gsp prevalence. Numbers in bold correspond to tumors presenting a rate over 10%. In each responsive tissue/organ,
incidences in the double digits often pinpoint a single diagnosis that stands out among other virtually gsp negative tumor types. The large majority of other
neoplasms are negative, for instance ref [50] analyzed 1126 cases falling within 15 diagnosis and found all negatives
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cAMP signaling in neoplastic transformation of selected
microenviroments. Chronic inflammation is often char-
acterized by gsp+ lesions. In pancreas, neoplastic lesions
including IPMN are typically associated to chronic in-
flammation and fibrosis. Gastric foveolar metaplasia in
the duodenum was considered a reactive process caused
by inflammatory conditions before a genetic component
was suggested by the higher gsp prevalence in trans-
formed areas as compared to the surrounding healthy
tissue. A correlation with the inflammatory process is
observed in liver, where gsp was reported to define a rare
subgroup of inflammatory tumors characterized by
STAT3 activation mediated by GNAS directly upregulat-
ing target genes of the inflammatory IL-6-STAT3 path-
way via Src [22].
Another puzzling link with inflammation is gsp inci-
dence within a spectrum of somatic mutations (TP53,
KRAS, SMAD4, CDKN2A, MLL3 and RNF43) shared by
pancreatic tumors and cholangiocarcinoma developing
in chronic inflammation induced by the parasite
Opisthorchis viverrini [23]. Upregulated PKA synergizes
with Wnt/β catenin to promote the slow progression of
the tumor. However, the more aggressive outcome with
Opisthorchis infection might be stimulated by the ex-
ogenous etiology of the inflammatory process.
Elevated Gαs activity can be accomplished by mul-
tiple mechanisms, or its consequences achieved by
other activators on the same pathway [24]. For in-
stance, in pituitary, gsp negative somatotroph tumors
show loss of methylation and biallelic GNAS expres-
sion, that is likely to translate in increased wt Gαs
expression [25, 26]. Cortisol-producing adenomas, an-
other gsp+ tumor (Table 2), shows that alterations of
components of Gαs downstream signaling pathway,
namely a defective form of the regulatory subunit of
PKA [27], could provide a surrogate of gsp activity in
preventing normal cell maturation and tissue
organization. Screens for somatic mutations in
cortisol-producing adenomas demonstrated mutually
exclusive mutations activating PKA and Gαs [28].
A better understanding of the pathogenesis triggered
by gsp would likely provide important diagnostic tools to
preoperatively predict the histological subtype for pan-
creatic lesions [29] and possibly others.
Functional consequences of gsp signaling
The classical signaling pathway portrayed downstream
of Gαs depicts the activation of adenylyl cyclase and a
consequent increase in cytosolic cAMP (Fig. 3). In turn,
cAMP interacts with the regulatory subunits of PKA set-
ting the catalytic subunits free to phosphorylate multiple
targets. Consistently, PKA is up-regulated in gsp+ neo-
plasms such as IPMN [30] or appendiceal adenoma [31].
But PKA activation may not be the sole target of gsp
signaling, as PKA mutations are not commonly reported
in sporadic cancers of the GI tract. At least in tissues
where gsp+ commonly occurs, this could suggest that
gsp activates additional targets in parallel to PKA. On
the other hand, the very rare Carney complex (CC, a
heterozygous, autosomal dominant syndrome caused by
mutations up-regulating PKA in all tissues), partially
overlaps MAS symptoms including adrenocortical, pitu-
itary, thyroid, skin tumors and pigmented lesions, myx-
omas (combined with FD symptoms is defined
Mazabraud's syndrome), schwannomas, liver cancer and
even IPMN [32]. Widespread PKA activation in all cells
may phenocopy more focal lesions that contin a gsp+
mutation within susceptible tissue.
In cortical cells renewing adrenal cortex, GNAS and
PKA mutations produce benign lesions that lead to Cush-
ing disease. Nonetheless, there are some distinctions: gsp
produces micronodular disease in MAS or ACTH-
independent macronodular hyperplasia, and, occasionally
cortisol producing adenoma; PKA mutations produce pri-
mary pigmented nodular adrenocortical disease [33].
The molecular consequences of the upregulation of the
Gs->cAMP->PKA axe on different tissue microenviron-
ments remains to be clarified. Essential targets for activa-
tion in gsp neoplasias have not yet been identified but
candidates include PKA and its substrates, such as AKAP
and other scaffolding proteins, ion channels, receptor
tyrosine kinases, and cAMP response element-binding
(CREB) protein that drives transcription of cAMP-
responsive element-containing genes [34, 35], PKA func-
tional and structural interaction with the EGF receptor
[36] could be particularly relevant. Gαs could promote cell
proliferation by PKA-dependent cross-talk with the EGF
pathway at multiple levels, but in particular at the level of
KRAS. KRAS is one of the most frequently mutated genes
in human tumors [37] and its simultaneous expression
with gsp is found in certain tumor types.
Thyroid carcinoma express activating mutations of
Gαs (12.5%), most commonly with activating mutations
of the KRAS-paralog NRAS (8.5%). The co-occurrence
of mutations simultaneously activating Gαs and KRAS is
not rare in tumors like IPMN but may be coincidental,
perhaps resulting from contamination of samples with
cells from two independent origins.
However, in other tumor types, like pituitary [38] or
muscle [37, 39], activating mutations of Ras family mem-
bers are extremely rare and associated with malignant
features, likely representing a late event in tumor pro-
gression. In any case, activating alleles of GNAS cer-
tainly occur in cancer independently of activating alleles
of KRAS (Table 1).
Although synergy between GNAS and KRAS is not
obvious, multiple studies analyzed the simultaneous
presence of both oncogenes. Whereas some cases found
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a positive correlation [40, 41], others observed different
frequencies of mutations affecting KRAS and GNAS as
in colloid vs. tubular subtypes of invasive IPMN. This
may suggest two separate progression pathways [19]
supporting previous findings in papillary neoplasms of
the bile duct [42, 43].
Cooperative signaling between Gαs and Kras proteins
was recently demonstrated in a mouse model of IPMN.
Conditional expression of gsp increased intracellular
cAMP concentration and fibrosis, but mice developed
IPMN-like lesions, with PKA activation and mucin over-
production, as in human, only when mutant KRAS was
co-expressed. [44] Gsp may provide a selective advantage
to cell precursors that, instead of undergoing normal dif-
ferentiation, become an indolent neoplasm usually de-
scribed by a relatively rare and fine-focused diagnosis
showing precise histologic characteristics. Retrospective
analysis reported hepatobiliary and pancreatic neoplasms
in about 30% of MAS patients [45–47]. Cell autonomous
signals produced by the activation of both pathways are
likely to converge as cAMP controls MAPK signaling at
multiple levels.
Field effect (i.e. the existence of histologically abnor-
mal microfoci within apparently normal tissue that pre-
disposes to the occurrence of simultaneous and
independent primary tumors) [43, 48] may also contrib-
ute to disease progression. For example, gsp is present in
about half of IPMN samples but TCGA identified acti-
vating alleles of GNAS with wild type KRAS in only 3%
of PDA. By contrast, about half of IPMN samples and
upwards of 92% of PDA have activating alleles of KRAS
but wild type GNAS (Table 1). This suggests gsp may
contribute to chronic pancreatic disease but secondary
mutations, such as KRAS activation, are necessary for
transformation and tumor progression [43, 49]. Mosaic
analysis is required to determine whether cell autono-
mous signaling or field effect explain the apparent inter-
action between Kras and Gαs proteins.
Tissue and cell specificity
Although Gαs is ubiquitously expressed, gsp only pro-
duces significant consequences in “permissive organs”
[1, 50]. As mentioned in the first paragraph, in almost
all endocrine tissues GNAS is transcribed from the ma-
ternal allele [51], therefore a predominance of gsp vs
WT GNAS caused by tissue specific imprinting could
partially explain why penetrance is so low elsewhere.
In adult pituitary, Gαs is monoallelically expressed
from the maternal allele and indeed Hayward et al. iden-
tified the mutation in the maternal allele in 21 out of 22
GH-secreting adenoma analyzed. Yet, imprinting was re-
laxed for GNAS while still fully in place for the other
genes belonging to the same locus (NESP55 and XLαs)
[52]. In bone, the paternal allele is not differentially
methylated and both alleles are expressed as in other
pluripotent stem cells [9]. Imprinting by itself is there-
fore insufficient to explain tissue specificity.
Even in the same tissue, gsp oncogenic effects can be
highly lineage cell specific and prevent, rather than pro-
mote, proliferation/survival. [53] In pituitary, the
Fig. 3 GPCR signaling is functional to almost any aspect of cell physiology including the organization of the stem cells niche. Gs coupled
receptors like LGR and PTHR cooperate with FZD producing very articulated downstream signalling that is also modulated by single
transmembrane domain co-receptors. Here a highly simplified scheme representing signalling intermediates described in the text. Multiple arrows
indicate indirect activation. In the callout, congenital diseases associated to mutations upregulating the downstream pathway
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mutation emerges as a proliferatory stimulus only in
GH-secreting cells while in other pituitary cells derived
from common progenitors (gonadotroph or lactotroph
derived) cAMP accumulation inhibits growth [26].
In the skin, gsp has never been associated with neo-
plastic growth. On the contrary, in an animal model of
basal-cell carcinogenesis the Gs–PKA axis was recently
shown to play an important tumor suppressive role. By
controlling s-HH and Hippo signaling PKA defined the
size of the stem cell compartment limiting self-renewal.
Upregulating its signaling by exogenous gsp expression
caused hair follicle stem cells exhaustion [54]. Consist-
ently, in MAS the presence of gsp does not promote
melanoma but only causes hyperpigmentation of mela-
nocytes by upregulating tyrosinase gene [55].
Several issues should be addressed before we under-
stand the basis of such tissue- and cell-specificity.
Among them, cell lineage specific expression of Gαs ef-
fector isoforms (that include 10 adenylyl cyclases iso-
forms, 2 PKA catalytic subunits [26]) or the mechanisms
opposing the increased cAMP levels (i.e. 11 subfamilies
of phosphodiesterases [56]).
Tissue specific expression of different transcripts
and alternative compartmentalization of Gαs may also
differentiate the response by restricting signaling at
precise subcellular locations [57, 58]. Traditionally,
heterotrimeric G protein signaling has been described
only at the plasma membrane. Acylated Gαs is an-
chored to the plasma membrane, but the post-
translational modification is reversible and Gαs is also
found cytosolic, particularly in the constitutively ac-
tive form. [59] Recently, it became clear that upon
GPCR activation, internalized receptors produce intra-
cellular signaling by upregulating adenylyl cyclase lo-
cated in the endosomal compartment [60, 61].
cAMP is a diffusible signaling molecule but is con-
centrated in local microdomains due to the action of
phosphodiesterases [62]. Another potential mechanism
to determine “cell specific” responses comes from the
subcellular localization of PKA [33] mediated by AKAP
that scaffolds several components of the pathway men-
tioned above [63] (Fig. 3). The list could continue, but
summarizing, the expression of a constitutively active
mutant is expected to affect the signaling network at
multiple districts and unlikely to entirely mimic the
stimulus of a Gs coupled receptor, nor to produce a
generalized cAMP increase. The implications on cell
physiology are unpredictable but may explain the differ-
ent phenotypes observed in MAS vs Carney complex
and the absence of phenotype in most tissues of the or-
ganism. More work is required to identify the critical
steps in neoplastic transformation, beginning with the
most relevant Gs mediated pathways in each tissue spe-
cific cell type (Fig. 4).
A GPCR perspective of the niche microenvironment
The analysis of GNAS in neoplasias of the gastrointes-
tinal tract is shedding new light on the significance of
the mutation. Gastric adenocarcinoma and most gastric
tumors are gsp negative (Table 2). Conversely, gastric
neoplasia of fundic gland and pyloric gland adenoma are
gsp+. Both subtypes are rare and share neck cell/chief
cell lineage phenotype [64]. In the normal gastric mu-
cosa, the digestive-enzymes secreting chief cells differen-
tiate from mucous neck cells via trans-differentiation
[65]. Neoplastic cells possess characteristics of immature
chief cells transitioning from mucous neck cells to ser-
ous chief cells. Probably, the same diversion from ad-
vanced phases of the differentiation program occurs in
the intestine where a potential histogenic link is ob-
served between these gastric lesions and analogous le-
sions appearing as gastric foveolar epithelium but
commonly present in duodenal biopsy specimens [66].
Depending on the absence or presence of oxyntic glands,
these lesions are classified into gastric foveolar metapla-
sia or gastric heterotopia. Microdissection-based analysis
of three gastric heterotopia lesions identified common
GNAS mutations in both components of the gastric mu-
cosa: foveolar epithelium and oxyntic glands suggesting
that the initial mutation occurred in stem cells, before
they differentiated into both epithelial components and
that the mutation did not cause detectable morpho-
logical changes in oxyntic glands [66]. This scenario is
reminiscent of osteoblasts maturation described above.
In pituitary, gsp emerges only in somatotrophs that
can also transdifferentiate from closely-related secretory
cells. The emerging picture is that GNAS activating mu-
tations allow cell survival only after a specific commit-
ment has been undertaken and confer growth advantage
only to precise lineages.
Stem cell self-renewal is critical in embryos and in
adult to repopulate tissues undergoing continuous reno-
vation. Cross-talk from multiple ligands evoking Gs-
signaling orchestrates self-renewal: Wnt, sHH and R-
spondins being among the best-described examples.
GPCR signaling is also involved in the differenti-
ation of immature progenitors during cell migration.
Leucine-rich repeat-containing G-protein coupled re-
ceptors (LGRs) regulate maturation of adult stem cells
during renewal of papillary intestine mucosa or the
patterning of hepatic lobules. In other tissues analo-
gous processes coordinately regulate maturation, mi-
gration, and proliferation. For instance, adrenal cortex
undergoes constant cell renewal as proliferation in
the outer cortex continues with centripetal cell migra-
tion and differentiation according to cell location
along the cortex medulla axis. Angiotensin II and
ACTH signaling are crucial for modulating the size of
each zone [67].
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The same GPCR acting during development or in
adult stem cell niches may also regulate the termin-
ally differentiated cell. Examples include ACTH
signaling to MC2R in zona fasciculata differentiation
of adrenal cortex, PTH in osteoblasts, and LH
gonadotropin in Leydig cells. In these cells, trophic
hormones evoke Gαs-cAMP dependent growth and
hormone release. Many exocrine or endocrine organs
are among those affected by constitutively active Gs
protein (see Table 2 and Fig. 4). Consistent with the
clinical features presented by affected patients [68],
glyco-proteins are secreted in IPMN [21, 42], IPNN
of the bile duct [42], duodenum [66], appendix [69],
cervical mucosa [70] by glands trans-differentiated to-
wards a gastric phenotype, and hormones are secreted
in pituitary (GH), thyroid (TSH), and gonads (LH and
FSH).
Hence, multiple examples support the idea that gsp
may bypass GPCR mediated signals to subvert differenti-
ation and promote proliferation in progenitor cells ra-
ther than terminally differentiated cells.
cAMP and Wnt signaling pathways
Wnt has been implicated in the oncogenesis of all “per-
missive tissues” of the gsp mutation (thyroid [71], bone
[72], pituitary [73], stomach [74], intestine [75], colon,
pancreas, adrenocortical [76]). In adrenal cortex, gene
expression analysis aimed at understanding cAMP
tumorigenic activity indicated cell cycle and Wnt signal-
ing as the most affected pathways [33].
Concerted cAMP and Wnt signaling is likely to repre-
sent a hallmark of gsp+ neoplasias. Cross-talk could
occur at any level of the signaling cascade. Wnt activates
intracellular signaling by simultaneously interacting with
two co-receptors: a lipoprotein receptor-related protein
(LRP5/6) and one out of ten members of the Frizzled
family (FZD1-10) characterized by conserved cysteine-
rich domain and seven transmembrane domains. In
addition to coupling Gs and other heterotrimeric G pro-
teins, FZDs interact with the scaffolding protein dishev-
eled. [77] As a result, FZDs act upstream of three
principal signaling mechanisms: the ‘canonical’, “planar
cell polarity” and ‘calcium’ pathways [78].
Fig. 4 GPCR dependent production of intracellular cAMP determines secretory function in specialized cells of different exocrine organs. Among
GPCRs determinant for the differentiation and function of tissues displaying the gsp+ phenotype, are secretin family receptors (glucagon, GIP,
secretin, VIP, GHRH) and LGR receptors (LGR 1-8). The same pathways instrumental to zonation and differentiation are also likely acting on
transcriptional programs related to the differentiation stage reached by the cells. NR5A master regulators are present in cells displaying the gsp+
phenotype (thyroid [95], osteoblast [93], somatotropic, pancreatic cells [98], hepatocytes, intestinal crypt [91], adrenocortical, Leydig and granulosa
cells [99])
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Interestingly, in addition to FZDs, several classical
GPCRs interact with LRP6 and activate downstream sig-
naling. These include prostaglandin E2 and F2, M1 acetyl-
choline muscarinic, lysophosphatidic acid, gonadotrophin-
releasing hormone and PTH type 1 (PTH1R) receptors.
In the canonical pathway, FZDs activates β-catenin by
disassembly of an intracellular inhibitory complex
formed by GSK3, adenomatosis polyposis coli (APC),
axin and casein kinase Iα (CKIα). Wnt stimulation pre-
vents the formation of the complex, cytoplasmic β-
catenin is stabilized, and translocates to the nucleus to
associate with transcription factors.
Hashimoto et al. analyzed a cohort of 20 patients af-
fected by familial adenomatous polyposis with inherited
APC mutations. Out of 6 cases with associated pyloric
gland adenomas of the stomach, 5 were gsp+, all carry-
ing APC mutations and high nuclear β-catenin expres-
sion levels [79]. All other patients and other types of
lesions (foveolar adenoma and fundic gland polyps) were
gsp negative.
The cooperative effect of gsp and APC inactivation
was also demonstrated in animal models of intestinal
tumor formation [75]. A correlation between the two
pathways is supported by animal models in which in-
creased PKA activity led to high prostaglandin E2 levels
and activated Wnt signaling [33, 80].
In colon cancer without functional APC, cell prolifera-
tion is stimulated by the proinflammatory metabolite
prostaglandine E2, an agonist for the Gs-coupled EP2.
Under these circumstances, Gαs-GTP, activated either
by the ligand or by mutation, directly interacts with the
RGS homology (RH) domain of axin. The interaction
sets GSK-3β free from the complex and leads to the
stabilization and nuclear translocation of β-catenin [81].
Analogously, PTH1R was shown to promote the direct
association of Gαs-GTP with axin [82].
Other critical points of convergence of the two pathways
may involve less well characterized signaling intermedi-
ates. An emerging finding shared by ovarian development
and digestive mucosa or adrenal cortex regeneration me-
diated by adult stem cells [83], is the involvement of a pro-
tein complex module featuring (Fig. 3):
– Wnt binding to FZD and LRPs
– a family of four cysteine rich proteins R-spondins
(Rspo1-4) binding to LGR 4, 5 and 6
– E3 ubiquitin ligases ZNRF3 and RNF43.
RNF43 and the closely related homolog ZNFR43 act
as co-receptors to transduce signaling across the plasma
membrane, they target cytosolic loops of FZD promoting
its ubiquitination, internalization and degradation [84].
Mutations inactivating RNF43/ZNRF43 are expected to
reduce FZD ubiquitination and to upregulate Wnt
signaling. Similar genetic anomalies are observed in ap-
proximately 90% of colorectal cancers as well as in other
cancer types, such as hepatocellular carcinomas or gas-
tric cancers [33] including most gsp+ neoplasias: liver
fluke associate cholangiocarcinoma, IPMN, ovary [85],
adrenocortical carcinomas [80, 86]. In addition to muta-
tions, epigenetics or other regulatory mechanisms redu-
cing RNF43 expression could play an analogous effect
synergizing with GNAS in the formation of IPMN and
other neoplasia in the pancreas [87].
PKA was shown to phosphorylate and upregulate β-
catenin signaling [88, 89] possibly in conjunction with
other transcription factors. In adrenal tumors autono-
mously producing cortisol, gain of function mutations in
β-catenin and in either Gαs or PKA were reported as
mutually exclusive [90]. Other transcription factors regu-
lated by cAMP are two nuclear receptors binding to the
same consensus sequences and named steroidogenic fac-
tor 1 (SF-1/NR5A1) and liver receptor homologue 1
(LRH-1/NR5A2).
NR5A2 has an important role in the gastrointestinal
system regulating functions such as bile acid and pan-
creatic fluid biosynthesis and secretion, glucose sensing
and cell renewal in the crypt. The latter aspect is medi-
ated by the interaction with CREB and β-catenin [91]. In
addition to being expressed in the intestinal crypt cells
[92], NR5A2 is also expressed by osteoblasts [93].
NR5A1 expression profile is restricted to adrenal cortex,
gonads, spleen, pituitary, gonadotropes, hypothalamic
VMN [94]. NR5A1 target genes are implicated at every
level of the hypothalamic-pituitary-gonadal axis and go-
nadal or adrenal steroidognesis [94].
An interplay between Wnt and ACTH->cAMP->PKA
pathways within the process of renewal and lineage con-
version has been suggested in zona fasciculata develop-
ment of the adrenal cortex. The mechanism portrays
PKA phosphorylation of NR5A1. A subtle balance be-
tween Wnt and PKA activation determines functional
zonation titrating NR5A1 and β-catenin. By this means,
Wnt and Adrenocorticotropric Hormone (ACTH)
stimulation determine and maintain cortex renewal. [67]
NR5A1 regulation by cAMP is also reported to direct
functional differentiation of thyroid progenitor cells and
to be involved in adenoma development [95]. NR5A2
was shown to play a role in intestine tumorigenesis con-
trolling enterocytes cell cycle and inflammatory cyto-
kines. NRA5A2 is a susceptibility locus for human
pancreatic cancer. Intriguingly, in an animal model of
KRAS driven neoplasia, NRA5A2 function constrains
tumor initiation [96].
By compromising the correct tuning of Wnt signaling,
gsp would thus distort the cellular response to surround-
ing signals. However, since an optimal level of Wnt/βca-
tenin signaling is essential to tumor formation [97], a
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constitutive activation of Gαs may not necessarily allow
full transformation [43] explaining why the oncogenic
effect is manifest only under specific circumstances in
permissive tissues.
In summary, loss-of-function mutations in the Wnt
signalosome that inhibit β-catenin may synergize with
gsp, suggesting that.constitutive Gαs activity lowers Wnt
signaling activation threshold.
Conclusions
Gsp is emerging as an oncogene acting in multifactorial
transformation processes in low-grade or benign neopla-
sia. In the digestive tract, it is often associated with pap-
illary morphology and high mucin secretion, reminiscent
of previously described endocrine tumors. High Gαs ac-
tivity may interfere with signaling in immature stages
but is not sufficient to progress to invasive carcinoma.
Therefore, gsp could be a marker for differential diagno-
sis of early neoplasia.
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